Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

Background Tumor endothelial marker 1 (TEM1) is a protein expressed in the tumor-associated endothelium and/or stroma of various types of cancer. We previously demonstrated that immunization with a plasmid-DNA vaccine targeting TEM1 reduced tumor progression in three murine cancer models. Radiation...

Full description

Bibliographic Details
Main Authors: Stefano Pierini, Abhishek Mishra, Renzo Perales-Linares, Mireia Uribe-Herranz, Silvia Beghi, Andrea Giglio, Sergei Pustylnikov, Francesca Costabile, Augusto Amici, John G Facciponte, Costantinos Koumenis
Format: Article
Language:English
Published: BMJ Publishing Group 2021-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/2/e001636.full

Internet

https://jitc.bmj.com/content/9/2/e001636.full

Similar Items